Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

— Successfully demonstrates strong tolerability, sustained drug release and safety

SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.

Read more at globenewswire.com